The article discusses the development of a Risk Evaluation and Mitigation Strategy (REMS) for fentanyl buccal tablet or FENTORA and ACTIQ which was approved by the U.S. Food and Drug Administration (FDA) in July 2011. It notes on action taken to lessen the risk of misuse and serious complications due to medication error by giving right prescription, prevention of inappropriate conversion between fentanyl products and proper education to pharmacists and patients about the misuse of these drugs.